C9orf153 Inhibitors
The functional activity of C9orf153 is intricately regulated by a network of signaling pathways and post-translational modifications, where its inhibition can be achieved through several biochemical mechanisms. One such mechanism involves the obstruction of kinase-mediated phosphorylation critical to C9orf153's activation. Certain inhibitors function by directly targeting these kinases, preventing the phosphorylation events required for C9orf153 to function optimally. This blockade of phosphorylation effectively diminishes C9orf153's activity. Similarly, the inhibition of specific lipid kinases that modulate upstream signals can lead to a downstream decrease in C9orf153's functional activity. By halting the activity of these lipid kinases, the signal transduction processes that contribute to the regulation of C9orf153 are disrupted, culminating in the reduction of its functional state. Moreover, the targeting of key regulatory pathways involving stress-activated proteins can indirectly mitigate the activity of C9orf153 by preventing essential regulatory phosphorylations.
Additionally, certain inhibitors exert their effects by impeding the proteolytic turnover of regulatory proteins that interact with or govern the function of C9orf153. This proteasome inhibition results in the accumulation of proteins that would otherwise be degraded, leading to an indirect inhibition of C9orf153's activity by perturbing the normal regulatory mechanisms. Other compounds interfere with the cellular acetylation patterns, thereby modifying gene expression and potentially altering the levels or activity of proteins that interact with C9orf153. Inhibition of kinase activity also plays a critical role, where the selective targeting of tyrosine kinases involved in phosphorylating substrates that regulate C9orf153 leads to a decrease in its functional activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor that broadly targets various kinases, including those that phosphorylate C9orf153. By inhibiting these kinases, staurosporine would prevent the phosphorylation of C9orf153, which is critical for its activation, leading to decreased functional activity of C9orf153. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a selective inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream regulators of multiple signaling pathways, including those involving C9orf153. Inhibition of PI3K disrupts the activity of downstream effectors that might modulate C9orf153 function, leading to an indirect decrease in its functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a specific inhibitor of MEK1/2, key enzymes in the MAPK/ERK pathway. The MAPK/ERK pathway can phosphorylate substrates that interact with or regulate C9orf153. By inhibiting MEK1/2, U0126 would hinder the phosphorylation events necessary for the proper functionality of C9orf153, thus indirectly inhibiting its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTOR (mammalian target of rapamycin), which is a central regulator of cell growth and proliferation. mTOR signaling can regulate the synthesis and turnover of proteins including C9orf153. The inhibition of mTOR by rapamycin may lead to a reduction in C9orf153 levels or activity, contributing to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which is involved in the MAPK/ERK pathway. This pathway can modulate various proteins including C9orf153. By inhibiting MEK, PD 98059 could reduce C9orf153 activity by preventing the necessary phosphorylation events. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a selective inhibitor of p38 MAPK, a key player in stress-activated MAPK pathways. p38 MAPK can modulate the activity of various proteins, and its inhibition by SB 203580 could lead to reduced regulatory phosphorylation events on proteins like C9orf153, indirectly inhibiting its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is implicated in controlling a number of cellular processes. JNK activity can lead to the phosphorylation of substrates that may regulate C9orf153. Inhibiting JNK with SP600125 could therefore prevent phosphorylation required for the optimal functioning of C9orf153, leading to an inhibition of its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, which is involved in multiple signaling pathways, including those that could regulate C9orf153. By inhibiting PI3K, wortmannin would disrupt the activity of downstream signaling molecules that could influence the function of C9orf153, leading to its decreased activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. By inhibiting the proteasome, bortezomib could lead to the accumulation of regulatory proteins that are ubiquitinated for degradation. This accumulation may indirectly inhibit C9orf153 activity by disrupting the normal regulatory processes in which C9orf153 is involved. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that targets BCR-ABL and Src family kinases. These kinases can phosphorylate proteins that interact with or regulate C9orf153. Inhibition of these kinases by dasatinib could lead to a decrease in phosphorylation events necessary for the activity of C9orf153, thereby indirectly inhibiting its functional activity. | ||||||